Bio-Techne Corp (TECH) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Total Assets Chart for Bio-Techne Corp
Bio-Techne Corp (TECH) total assets for FY2026 were USD 2.6B, a 1.1% change from FY2025. Bio-Techne Corp's total assets grew from USD 6.1M in 1989 to USD 2.6B in 2026 (42305.3% over 37 years). Total assets compound annual growth rate: 5-year CAGR of 2.7%, 10-year CAGR of 8.6%, 20-year CAGR of 10.2%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $11.28B
- Implied Share Price
- $72.40
- Enterprise Value
- $11.31B
- Revenue (TTM)
- $1.22B
- EBITDA
- $355.05M
- Profit Margin
- 14.97%
- Trailing P/E
- 62.41
- Forward P/E
- 34.60
- Price/Book (MRQ)
- 5.35
- Price/Sales (TTM)
- 9.28
- EV/EBITDA
- 32.37
- EV/Revenue
- 9.31
- Dividend Yield
- 0.44%
- Book Value
- $13.32
- Free Cash Flow (FY2026)
- $263.22M
- Free Cash Flow Yield
- 2.33%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.